USANA Health Sciences, Inc. (NYSE:USNA) Shares Sold by Shell Asset Management Co.

Shell Asset Management Co. reduced its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNAGet Rating) by 12.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 6,336 shares of the company’s stock after selling 936 shares during the period. Shell Asset Management Co.’s holdings in USANA Health Sciences were worth $503,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. ProShare Advisors LLC purchased a new position in USANA Health Sciences during the 4th quarter worth $303,000. Covestor Ltd purchased a new stake in shares of USANA Health Sciences in the fourth quarter valued at about $49,000. Crew Capital Management Ltd. purchased a new stake in shares of USANA Health Sciences in the fourth quarter valued at about $202,000. Citigroup Inc. boosted its holdings in shares of USANA Health Sciences by 25.8% in the fourth quarter. Citigroup Inc. now owns 11,598 shares of the company’s stock valued at $1,174,000 after acquiring an additional 2,378 shares in the last quarter. Finally, Summit Global Investments boosted its holdings in shares of USANA Health Sciences by 1.6% in the fourth quarter. Summit Global Investments now owns 18,551 shares of the company’s stock valued at $1,877,000 after acquiring an additional 300 shares in the last quarter. 55.72% of the stock is owned by hedge funds and other institutional investors.

USANA Health Sciences Trading Up 1.9 %

USNA stock opened at $70.83 on Thursday. The company has a market cap of $1.36 billion, a P/E ratio of 15.60 and a beta of 0.72. The company’s 50-day moving average price is $70.89 and its 200 day moving average price is $78.87. USANA Health Sciences, Inc. has a 52 week low of $63.49 and a 52 week high of $103.95.

USANA Health Sciences (NYSE:USNAGet Rating) last announced its earnings results on Tuesday, July 26th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.05). USANA Health Sciences had a return on equity of 22.49% and a net margin of 8.27%. During the same quarter last year, the firm posted $1.87 EPS. On average, equities research analysts expect that USANA Health Sciences, Inc. will post 3.98 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on USNA shares. StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 26th. DA Davidson reissued a “maintains” rating on shares of USANA Health Sciences in a report on Thursday, July 28th. Finally, Jefferies Financial Group downgraded shares of USANA Health Sciences from a “hold” rating to an “underperform” rating and decreased their price objective for the stock from $78.00 to $53.00 in a report on Thursday, July 7th. One investment analyst has rated the stock with a sell rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $77.33.

Insiders Place Their Bets

In other USANA Health Sciences news, Director Gilbert A. Fuller sold 404 shares of USANA Health Sciences stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $70.00, for a total transaction of $28,280.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO G Doug Iiekking sold 1,086 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $70.51, for a total value of $76,573.86. Following the completion of the transaction, the chief financial officer now owns 1,838 shares of the company’s stock, valued at $129,597.38. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Gilbert A. Fuller sold 404 shares of the business’s stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $70.00, for a total transaction of $28,280.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,202 shares of company stock worth $225,450. Insiders own 0.36% of the company’s stock.

USANA Health Sciences Profile

(Get Rating)

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products.

Featured Stories

Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNAGet Rating).

Institutional Ownership by Quarter for USANA Health Sciences (NYSE:USNA)

Want More Great Investing Ideas?

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.